Researchers looking to aggregate and harmonize genomic data—a critical undertaking that would empower translational research in pediatric oncology—will face technical complexities that exceed the challenges of enabling interoperability between electronic health record systems, said Jinghui Zhang, the St. Jude Endowed Chair in Bioinformatics and chair of the Department of Computational Biology at St. Jude Children’s Research Hospital.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
